Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341669 | 0.99 | MAPK14 (0.52) | MAPK14MCHR1ACHEHRH3 | |
| SCHEMBL3338467 | 0.92 | MAPK14 (0.47) | MAPK14MCHR1 | |
| SCHEMBL1140587 | 0.89 | MAPK14 (0.64) | MAPK14 | |
| Hydrochloric Acid SCHEMBL1140377 | 0.89 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL1140402 | 0.88 | MAPK14 (0.65) | MAPK14 | |
| SCHEMBL3108267 | 0.88 | MAPK14 (0.66) | MAPK14MCHR1 | |
| SCHEMBL3108389 | 0.88 | MAPK14 (0.55) | MAPK14MCHR1 | |
| SCHEMBL1140133 | 0.87 | MAPK14 (0.52) | MAPK14MCHR1 | |
| SCHEMBL1140310 | 0.87 | MAPK14 (0.65) | MAPK14 | |
| SCHEMBL1140580 | 0.86 | MAPK14 (0.61) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-7696215-B2 | 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL2RA | MAPK14 1418/4885MCHR1 938/4885ACHE 4772/4885 |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL1B | MAPK14 1400/4885MCHR1 800/4885ACHE 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.